Fierer J, Kirkland T, Finley F
Department of Medicine, Veterans Administration Medical Center, San Diego, California 92161.
Antimicrob Agents Chemother. 1990 Jan;34(1):13-6. doi: 10.1128/AAC.34.1.13.
We infected mice with arthroconidia of Coccidioides immitis by intraperitoneal injection and 48 h later treated them with either oral fluconazole or SDZ89-485, a new triazole. Both drugs completely inhibited fungal growth when administered at a dose of 50 mg/kg of body weight twice a day, but only SDZ89-485 was fully inhibitory at a dose of 5 mg/kg twice a day. In a second experiment, treatment with SDZ89-485 was delayed until 8 days after infection to allow infection to be well established before treatment. Both 5 and 50 mg/kg twice a day were effective regimens, which establishes that SDZ89-485 has activity against spherules in vivo. Mice that received fluconazole (50 mg/kg twice a day) had a peak level in blood of 60 micrograms/ml 1 h after a dose, but no measurable amount was found after 12 h. SDZ89-485 was more slowly absorbed, reaching a peak level in blood of 14 micrograms/ml at 12 to 15 h after a dose of 50 mg/kg. We conclude that SDZ89-485 is more effective than fluconazole as treatment for experimental systemic coccidioidomycosis in mice, even though fluconazole achieves higher peak levels in blood.
我们通过腹腔注射用粗球孢子菌的关节孢子感染小鼠,48小时后用口服氟康唑或一种新型三唑类药物SDZ89 - 485对其进行治疗。当以每天两次、50毫克/千克体重的剂量给药时,两种药物都能完全抑制真菌生长,但只有SDZ89 - 485在每天两次、5毫克/千克的剂量下具有完全抑制作用。在第二个实验中,将SDZ89 - 485的治疗推迟到感染后8天,以便在治疗前使感染充分确立。每天两次、5毫克/千克和50毫克/千克的剂量都是有效的治疗方案,这表明SDZ89 - 485在体内对球形体具有活性。接受氟康唑(每天两次、50毫克/千克)治疗的小鼠在给药后1小时血液中的峰值水平为60微克/毫升,但12小时后未检测到可测量的量。SDZ89 - 485吸收较慢,在给予50毫克/千克剂量后12至15小时血液中的峰值水平达到14微克/毫升。我们得出结论,尽管氟康唑在血液中达到较高的峰值水平,但SDZ89 - 485作为小鼠实验性系统性球孢子菌病的治疗药物比氟康唑更有效。